Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$65.27 USD
-1.81 (-2.70%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $65.09 -0.18 (-0.28%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Product Sales: Total HIV
- 18,175.00
- 17,194.00
- 16,315.00
- 16,938.00
- 16,438.00
- Revenue - Line of Business (LOBR)
- Product Sales: Total HCV
- 1,767.00
- 1,810.00
- 1,881.00
- 2,064.00
- 2,936.00
- Revenue - Line of Business (LOBR)
- Product Sales: Total Hepatitis B virus (HBV) / Hepatitis delta virus (HDV)
- 1,017.00
- 988.00
- 969.00
- 860.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Cell therapy: Total
- 1,869.00
- 1,459.00
- 871.00
- 601.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Trodelvy: Total
- 1,063.00
- 680.00
- 380.00
- 49.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Total Veklury
- 2,184.00
- 3,905.00
- 5,565.00
- 2,811.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Biktarvy: Total
- 11,850.00
- 10,390.00
- 8,624.00
- 7,259.00
- 4,738.00
- Revenue - Line of Business (LOBR)
- Product Sales: Descovy: Total
- 1,985.00
- 1,872.00
- 1,700.00
- 1,861.00
- 1,500.00
- Revenue - Line of Business (LOBR)
- Product Sales: Genvoya: Total
- 2,060.00
- 2,404.00
- 2,879.00
- 3,338.00
- 3,931.00
- Revenue - Line of Business (LOBR)
- Product Sales: Odefsey: Total
- 1,350.00
- 1,469.00
- 1,568.00
- 1,672.00
- 1,655.00
- Revenue - Line of Business (LOBR)
- Product Sales: Vemlidy: Total
- 862.00
- 842.00
- 814.00
- 657.00
- 488.00
- Revenue - Line of Business (LOBR)
- Revenues: Stribild: Total
- 101.00
- 127.00
- 189.00
- 196.00
- 369.00
- Revenue - Line of Business (LOBR)
- Antiviral products: Ledipasvir/Sofosbuvir: Total
- 70.00
- 115.00
- 212.00
- 272.00
- 643.00
- Revenue - Line of Business (LOBR)
- Revenues: Other Product: Total
- 225.00
- 253.00
- 281.00
- 276.00
- --
- Revenue - Line of Business (LOBR)
- Revenues: Product: Tecartus: Other International
- 15.00
- 3.00
- 0.00
- --
- --
- Revenue - Line of Business (LOBR)
- Total Liver Disease: Total
- 2,784.00
- 2,798.00
- 2,850.00
- --
- --
- Revenue - Line of Business (LOBR)
- Total Oncology: Total
- 2,932.00
- 2,139.00
- 1,251.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Product sales
- 26,934.00
- 26,982.00
- 27,008.00
- 24,355.00
- 22,119.00
- Revenue - Line of Business (LOBR)
- Revenues: Royalty contract and other revenues
- 182.00
- 299.00
- 297.00
- 334.00
- 330.00
- Revenue - Line of Business (LOBR)
- Product Sales: AmBisome
- 492.00
- 497.00
- 540.00
- 436.00
- 407.00
- Revenue - Line of Business (LOBR)
- Product Sales: HIV: Truvada
- 114.00
- 147.00
- 371.00
- 1,448.00
- 2,813.00
- Revenue - Line of Business (LOBR)
- Product Sales: Hepatitis B virus (HBV) / Hepatitis delta virus (HDV): Viread: Other Total
- 72.00
- 91.00
- 111.00
- 185.00
- 243.00
- Revenue - Line of Business (LOBR)
- Product Sales: Letairis
- 142.00
- 196.00
- 206.00
- 314.00
- 618.00
- Revenue - Line of Business (LOBR)
- Product Sales: Other
- 859.00
- 946.00
- 1,027.00
- 136.00
- 285.00
- Revenue - Line of Business (LOBR)
- Revenues: Complera / Eviplera: Total
- 129.00
- 200.00
- 258.00
- 269.00
- 406.00
- Revenue - Line of Business (LOBR)
- Product Sales: Tecartus: Total
- 370.00
- 299.00
- 176.00
- 44.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Hepatitis C virus (HCV): Total
- 160.00
- 166.00
- 207.00
- 193.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other HIV Total
- 56.00
- 27.00
- 195.00
- 407.00
- --
- Revenue - Line of Business (LOBR)
- Revenues: Sofosbuvir / Velpatasvir: Total
- 1,537.00
- 1,530.00
- 1,462.00
- 1,599.00
- 1,965.00
- Revenue - Line of Business (LOBR)
- Revenue share: Symtuza: Total
- 529.00
- 530.00
- 531.00
- 488.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Yescarta: Total
- 1,498.00
- 1,160.00
- 695.00
- 563.00
- 456.00
- Revenue - Geographic (GEOR)
- Product Sales: Biktarvy: U.S
- 9,692.00
- 8,510.00
- 7,049.00
- 6,095.00
- 4,225.00
- Revenue - Geographic (GEOR)
- Product Sales: Descovy: U.S
- 1,771.00
- 1,631.00
- 1,397.00
- 1,526.00
- 1,078.00
- Revenue - Geographic (GEOR)
- Product Sales: Genvoya: U.S
- 1,752.00
- 1,983.00
- 2,267.00
- 2,605.00
- 2,984.00
- Revenue - Geographic (GEOR)
- Product Sales: Odefsey: U.S
- 1,012.00
- 1,058.00
- 1,076.00
- 1,172.00
- 1,180.00
- Revenue - Geographic (GEOR)
- Revenue share: Symtuza: U.S
- 382.00
- 348.00
- 355.00
- 331.00
- 249.00
- Revenue - Geographic (GEOR)
- Revenues: Complera / Eviplera: United States
- 47.00
- 74.00
- 102.00
- 89.00
- 160.00
- Revenue - Geographic (GEOR)
- Revenues: Stribild: United States
- 72.00
- 88.00
- 132.00
- 125.00
- 268.00
- Revenue - Geographic (GEOR)
- Product Sales: HIV: Truvada: U.S.
- 82.00
- 113.00
- 314.00
- 1,376.00
- 2,640.00
- Revenue - Geographic (GEOR)
- Product Sales: Total HIV: US
- 14,848.00
- 13,820.00
- 12,828.00
- 13,651.00
- 13,315.00
- Revenue - Geographic (GEOR)
- Product Sales: Total HCV: U.S
- 1,002.00
- 1,005.00
- 1,018.00
- 1,088.00
- 1,465.00
- Revenue - Geographic (GEOR)
- Product Sales: Hepatitis B virus (HBV) / Hepatitis delta virus (HDV): Viread: Europe
- 22.00
- 23.00
- 28.00
- 34.00
- 69.00
- Revenue - Geographic (GEOR)
- Product Sales: Hepatitis B virus (HBV) / Hepatitis delta virus (HDV): Viread: Other International
- 52.00
- 62.00
- 72.00
- 137.00
- 142.00
- Revenue - Geographic (GEOR)
- Product Sales: Total HIV: Europe
- 2,102.00
- 2,219.00
- 2,366.00
- 2,287.00
- 2,312.00
- Revenue - Geographic (GEOR)
- Product Sales: Total HIV: Other international
- 1,226.00
- 1,155.00
- 1,121.00
- 1,000.00
- 811.00
- Revenue - Geographic (GEOR)
- Product Sales: U.S.
- 19,377.00
- 18,716.00
- 19,176.00
- 18,141.00
- 16,565.00
- Revenue - Geographic (GEOR)
- Product Sales: Europe
- 4,197.00
- 4,342.00
- 4,678.00
- 3,894.00
- 3,567.00
- Revenue - Geographic (GEOR)
- Product Sales: Other International
- 3,361.00
- 3,924.00
- 3,154.00
- 2,320.00
- 1,987.00
- Revenue - Geographic (GEOR)
- Revenues: Complera / Eviplera: Europe
- 70.00
- 113.00
- 142.00
- 159.00
- 214.00
- Revenue - Geographic (GEOR)
- Revenues: Complera / Eviplera: Other
- 12.00
- 13.00
- 14.00
- 21.00
- 32.00
- Revenue - Geographic (GEOR)
- Revenues: Stribild: Europe
- 21.00
- 29.00
- 43.00
- 54.00
- 75.00
- Revenue - Geographic (GEOR)
- Revenues: Stribild: Other International
- 8.00
- 10.00
- 14.00
- 17.00
- 26.00
- Revenue - Geographic (GEOR)
- Antiviral products: Harvoni /Ledipasvir/Sofosbuvir: U.S
- 39.00
- 46.00
- 84.00
- 92.00
- 312.00
- Revenue - Geographic (GEOR)
- Antiviral products: Harvoni /Ledipasvir/Sofosbuvir: Europe
- 12.00
- 17.00
- 31.00
- 29.00
- 71.00
- Revenue - Geographic (GEOR)
- Antiviral products: Harvoni /Ledipasvir/Sofosbuvir: Other International
- 19.00
- 51.00
- 97.00
- 151.00
- 260.00
- Revenue - Geographic (GEOR)
- Product Sales: Genvoya: Europe
- 205.00
- 284.00
- 391.00
- 490.00
- 664.00
- Revenue - Geographic (GEOR)
- Product Sales: Genvoya: Other International
- 103.00
- 136.00
- 221.00
- 243.00
- 283.00
- Revenue - Geographic (GEOR)
- Product Sales: Descovy: Europe
- 100.00
- 118.00
- 164.00
- 197.00
- 255.00
- Revenue - Geographic (GEOR)
- Product Sales: Odefsey: Europe
- 294.00
- 364.00
- 440.00
- 450.00
- 438.00
- Revenue - Geographic (GEOR)
- Product Sales: Vemlidy: U.S
- 410.00
- 429.00
- 384.00
- 356.00
- 309.00
- Revenue - Geographic (GEOR)
- Product Sales: Vemlidy: Europe
- 38.00
- 35.00
- 34.00
- 29.00
- 21.00
- Revenue - Geographic (GEOR)
- Product Sales: Vemlidy: Other International
- 414.00
- 379.00
- 396.00
- 272.00
- 158.00
- Revenue - Geographic (GEOR)
- Product Sales: Yescarta: U.S
- 811.00
- 747.00
- 406.00
- 362.00
- 373.00
- Revenue - Geographic (GEOR)
- Revenue share: Symtuza: Europe
- 133.00
- 168.00
- 165.00
- 159.00
- 130.00
- Revenue - Geographic (GEOR)
- Product Sales: Veklury: U.S
- 972.00
- 1,575.00
- 3,640.00
- 2,026.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Veklury: Europe
- 408.00
- 702.00
- 1,095.00
- 607.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Veklury: Other International
- 805.00
- 1,628.00
- 830.00
- 178.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Total HCV: Europe
- 378.00
- 413.00
- 421.00
- 414.00
- 742.00
- Revenue - Geographic (GEOR)
- Product Sales: Total HCV: Other International
- 386.00
- 392.00
- 442.00
- 562.00
- 729.00
- Revenue - Geographic (GEOR)
- Revenues: Sofosbuvir / Velpatasvir: U.S
- 859.00
- 844.00
- 815.00
- 864.00
- 971.00
- Revenue - Geographic (GEOR)
- Revenues: Sofosbuvir / Velpatasvir: Europe
- 323.00
- 355.00
- 316.00
- 337.00
- 553.00
- Revenue - Geographic (GEOR)
- Revenues: Sofosbuvir / Velpatasvir: Other International
- 355.00
- 331.00
- 331.00
- 398.00
- 441.00
- Revenue - Geographic (GEOR)
- Product Sales: Biktarvy: Europe
- 1,253.00
- 1,103.00
- 969.00
- 735.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Biktarvy: Other International
- 905.00
- 777.00
- 606.00
- 429.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Descovy: Other International
- 114.00
- 123.00
- 139.00
- 138.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Odefsey: Other International
- 44.00
- 47.00
- 52.00
- 50.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other HIV: U.S
- 37.00
- 15.00
- 136.00
- 332.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other HIV: Europe
- 12.00
- 24.00
- 30.00
- 26.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other HIV: Other International
- 7.00
- 17.00
- 29.00
- 49.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Hepatitis C virus (HCV): U.S
- 104.00
- 115.00
- 119.00
- 132.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Hepatitis C virus (HCV): Europe
- 43.00
- 40.00
- 74.00
- 48.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Hepatitis C virus (HCV): Other International
- 12.00
- 10.00
- 14.00
- 13.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Total Hepatitis B virus (HBV) / Hepatitis delta virus (HDV): U.S
- 418.00
- 435.00
- 397.00
- 380.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Total Hepatitis B virus (HBV) / Hepatitis delta virus (HDV): Europe
- 133.00
- 112.00
- 104.00
- 409.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Total Hepatitis B virus (HBV) / Hepatitis delta virus (HDV): Other International
- 466.00
- 441.00
- 468.00
- 409.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Tecartus: U. S
- 245.00
- 221.00
- 136.00
- 34.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Tecartus: Europe
- 110.00
- 75.00
- 40.00
- 10.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Yescarta: Europe
- 547.00
- 355.00
- 253.00
- 191.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Yescarta: Other International
- 140.00
- 57.00
- 36.00
- 10.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Cell therapy: U. S
- 1,055.00
- 968.00
- 542.00
- 396.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Cell therapy: Europe
- 658.00
- 430.00
- 293.00
- 201.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Cell therapy: Other International
- 156.00
- 60.00
- 36.00
- 10.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Trodelvy: U. S
- 777.00
- 525.00
- 370.00
- 380.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: Trodelvy: Europe
- 217.00
- 143.00
- 10.00
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Trodelvy: Other International
- 68.00
- 12.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: AmBisome: U.S.
- 43.00
- 57.00
- 39.00
- 61.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: AmBisome: Europe
- 260.00
- 258.00
- 274.00
- 230.00
- --
- Revenue - Geographic (GEOR)
- Product Sales: AmBisome: Other International
- 189.00
- 182.00
- 227.00
- 145.00
- --
- Revenue - Geographic (GEOR)
- Revenues: Other Product: Other: U.S.
- 118.00
- 135.00
- 136.00
- 176.00
- --
- Revenue - Geographic (GEOR)
- Revenues: Other Product: Other: Europe
- 40.00
- 65.00
- 115.00
- 84.00
- --
- Revenue - Geographic (GEOR)
- Revenues: Other Product: Other: Other International
- 66.00
- 53.00
- 30.00
- 16.00
- --
- Revenue - Geographic (GEOR)
- Revenue share: symtuza: Other international
- 13.00
- 14.00
- 11.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Product-Other HBV/HDV(6): Europe
- 72.00
- 55.00
- 42.00
- --
- --
- Revenue - Geographic (GEOR)
- Total Liver Disease: US
- 1,421.00
- 1,440.00
- 1,415.00
- --
- --
- Revenue - Geographic (GEOR)
- Total Liver Disease: Europe
- 511.00
- 525.00
- 525.00
- --
- --
- Revenue - Geographic (GEOR)
- Total Liver Disease: Other International
- 852.00
- 833.00
- 910.00
- --
- --
- Revenue - Geographic (GEOR)
- Total Oncology: US
- 1,833.00
- 1,494.00
- 912.00
- --
- --
- Revenue - Geographic (GEOR)
- Total Oncology: Europe
- 875.00
- 573.00
- 303.00
- --
- --
- Revenue - Geographic (GEOR)
- Total Oncology: Other International
- 224.00
- 73.00
- 36.00
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: HIV: Truvada: Europe
- 13.00
- 15.00
- 22.00
- 27.00
- 101.00
- Revenue - Geographic (GEOR)
- Product Sales: HIV: Truvada: Other international
- 19.00
- 18.00
- 35.00
- 45.00
- 2,813.00
- Revenue - Geographic (GEOR)
- Product Sales: HIV: Viread: US
- 8.00
- 6.00
- 11.00
- 14.00
- 32.00